gepotidacin novel UTI
Selected indexed studies
- Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium. (Antibiotics (Basel), 2025) [PMID:41463692]
- Structure activity relationship of N-1 substituted 1,5-naphthyrid-2-one analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-9). (Bioorg Med Chem Lett, 2022) [PMID:35609741]
- Tarnished gold-the "standard" urine culture: reassessing the characteristics of a criterion standard for detecting urinary microbes. (Front Urol, 2023) [PMID:40778073]
_Worker-drafted node — pending editorial review._
Connections
gepotidacin novel UTI is a side effect of
Sources
- Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium. (2025) pubmed
- Structure activity relationship of N-1 substituted 1,5-naphthyrid-2-one analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-9). (2022) pubmed
- Tarnished gold-the "standard" urine culture: reassessing the characteristics of a criterion standard for detecting urinary microbes. (2023) pubmed
- In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis, and Staphylococcus saprophyticus. (2025) pubmed
- Pharmacokinetic and pharmacodynamic characterization of gepotidacin against Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh infection model. (2026) pubmed
- Novel Antibiotics for Urinary Tract Infection (UTI): The EAGLE 2 and EAGLE-3 Trials for Uncomplicated UTI, and the CERTAIN-1 Trial for Complicated UTI. (2024) pubmed